DK0995748T3 - Væksthormonsecerneringsfremkaldende stoffer - Google Patents

Væksthormonsecerneringsfremkaldende stoffer

Info

Publication number: DK0995748T3
Authority: DK; Denmark
Prior art keywords: growth hormone; compounds; useful; accelerating; present
Prior art date: 1998-08-21

Application number

DK99306576T

Other languages

English (en)

Inventor

Philip Albert Carpino

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-21

Filing date

1999-08-19

Publication date

2004-08-02

1999-08-19 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-08-02 Application granted granted Critical

2004-08-02 Publication of DK0995748T3 publication Critical patent/DK0995748T3/da

Links

102000018997 Growth Hormone Human genes 0.000 title abstract 4
108010051696 Growth Hormone Proteins 0.000 title abstract 4
239000000122 growth hormone Substances 0.000 title abstract 4
239000000411 inducer Substances 0.000 title 1
230000028327 secretion Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 abstract 2
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 abstract 2
208000001132 Osteoporosis Diseases 0.000 abstract 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
101710142969 Somatoliberin Proteins 0.000 abstract 2
229940011871 estrogen Drugs 0.000 abstract 2
239000000262 estrogen Substances 0.000 abstract 2
230000013632 homeostatic process Effects 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 abstract 1
NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 abstract 1
WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 abstract 1
RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 abstract 1
DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 abstract 1
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 abstract 1
102100033367 Appetite-regulating hormone Human genes 0.000 abstract 1
101710111255 Appetite-regulating hormone Proteins 0.000 abstract 1
229940122361 Bisphosphonate Drugs 0.000 abstract 1
208000010392 Bone Fractures Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
102000055006 Calcitonin Human genes 0.000 abstract 1
108060001064 Calcitonin Proteins 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
208000017667 Chronic Disease Diseases 0.000 abstract 1
208000036119 Frailty Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
230000032683 aging Effects 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 abstract 1
229940062527 alendronate Drugs 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
206010003549 asthenia Diseases 0.000 abstract 1
-1 bisphosphonate compound Chemical class 0.000 abstract 1
229960004015 calcitonin Drugs 0.000 abstract 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
230000001925 catabolic effect Effects 0.000 abstract 1
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 abstract 1
108010015153 growth hormone releasing hexapeptide Proteins 0.000 abstract 1
239000003324 growth hormone secretagogue Substances 0.000 abstract 1
108010070965 hexarelin Proteins 0.000 abstract 1
230000002503 metabolic effect Effects 0.000 abstract 1
210000003205 muscle Anatomy 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229940063238 premarin Drugs 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
238000011084 recovery Methods 0.000 abstract 1
230000004044 response Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
230000029663 wound healing Effects 0.000 abstract 1
229940126158 β3 adrenergic receptor agonist Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK99306576T 1998-08-21 1999-08-19 Væksthormonsecerneringsfremkaldende stoffer DK0995748T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9750298P	1998-08-21	1998-08-21

Publications (1)

Publication Number	Publication Date
DK0995748T3 true DK0995748T3 (da)	2004-08-02

Family

ID=22263698

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99306576T DK0995748T3 (da)	1998-08-21	1999-08-19	Væksthormonsecerneringsfremkaldende stoffer

Country Status (11)

Country	Link
US (3)	US6358951B1 (da)
EP (1)	EP0995748B1 (da)
JP (1)	JP3486137B2 (da)
AT (1)	ATE263168T1 (da)
BR (1)	BR9903870A (da)
CA (2)	CA2280587C (da)
DE (1)	DE69915968T2 (da)
DK (1)	DK0995748T3 (da)
ES (1)	ES2217694T3 (da)
MX (1)	MXPA03006951A (da)
PT (1)	PT995748E (da)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6358951B1 (en)	1998-08-21	2002-03-19	Pfizer Inc.	Growth hormone secretagogues
US6297380B1 (en)	1998-11-23	2001-10-02	Pfizer Inc.	Process and intermediates for growth hormone secretagogues
AP2002002641A0 (en) *	2000-04-07	2002-12-31	Pfizer Prod Inc	Estrogen agonist metabolites.
EP1289526A4 (en)	2000-05-30	2005-03-16	Merck & Co Inc	MELANOCORTIN RECEPTOR AGONISTS
ATE446758T1 (de)	2000-05-31	2009-11-15	Pfizer Prod Inc	Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
IL143690A0 (en) *	2000-06-19	2002-04-21	Pfizer Prod Inc	The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL143942A0 (en) *	2000-06-29	2002-04-21	Pfizer Prod Inc	Use of growth hormone secretagogues for treatment of physical performance decline
EP1181933A3 (en) *	2000-06-29	2002-04-10	Pfizer Products Inc.	Use of growth hormone secretagogues for stimulating or increasing appetite
IL144468A0 (en) *	2000-07-27	2002-05-23	Pfizer Prod Inc	Use of growth hormone secretagogues for improvement of functional health status
IL145106A0 (en) *	2000-08-30	2002-06-30	Pfizer Prod Inc	Intermittent administration of a geowth hormone secretagogue
IL145540A0 (en) *	2000-09-28	2002-06-30	Pfizer Prod Inc	Use of growth hormone secretagogues in conjunction with physical exercise
CA2372450A1 (en) *	2001-05-10	2001-09-19	Pharmaceutical Partners Of Canada Inc.	Liquid injectable formulation of disodium pamidronate
IL159270A0 (en) *	2001-06-14	2004-06-01	Yissum Res Dev Co	Non-myeloablative tolerogenic treatment with tyrphostins
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7476653B2 (en)	2003-06-18	2009-01-13	Tranzyme Pharma, Inc.	Macrocyclic modulators of the ghrelin receptor
US20050107350A1 (en) *	2003-08-22	2005-05-19	Pharmacia Corporation	Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
JP2005306839A (ja) *	2003-08-29	2005-11-04	Takeda Chem Ind Ltd	二環性ピペラジン化合物およびその用途
EP1661898A4 (en) *	2003-08-29	2009-04-15	Takeda Pharmaceutical	BICYCLIC PIPERAZINE COMPOUND AND ITS USE
AU2004274309B2 (en)	2003-09-22	2010-04-08	Msd K.K.	Novel piperidine derivative
US7504506B2 (en)	2003-11-04	2009-03-17	Elixir Pharmaceuticals, Inc.	Therapeutic compounds and uses thereof
EP1529533A1 (en) *	2003-11-06	2005-05-11	Sahltech I Göteborg AB	Use of GH secretagogues in hypoxic-ischemic brain injury
CA2561801A1 (en) *	2004-04-02	2005-10-20	Elixir Pharmaceuticals, Inc.	Sulfonamides and uses thereof
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
CA2577060A1 (en) *	2004-08-13	2006-02-23	Amgen Inc.	Substituted benzofused heterocycles
CA2609388C (en)	2005-05-30	2013-08-06	Banyu Pharmaceutical Co., Ltd.	Novel piperidine derivative
JPWO2007018248A1 (ja)	2005-08-10	2009-02-19	萬有製薬株式会社	ピリドン化合物
EP1921065B1 (en)	2005-08-24	2010-10-20	Banyu Pharmaceutical Co., Ltd.	Phenylpyridone derivative
WO2007029847A1 (ja)	2005-09-07	2007-03-15	Banyu Pharmaceutical Co., Ltd.	二環性芳香族置換ピリドン誘導体
BRPI0616463A2 (pt)	2005-09-29	2011-06-21	Merck & Co Inc	composto, composição farmacêutica, e, uso de um composto
WO2007048027A2 (en)	2005-10-21	2007-04-26	Novartis Ag	Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AU2006307046A1 (en)	2005-10-27	2007-05-03	Msd K.K.	Novel benzoxathiin derivative
US8158791B2 (en)	2005-11-10	2012-04-17	Msd K.K.	Aza-substituted spiro derivatives
CU23558A1 (es)	2006-02-28	2010-07-20	Ct Ingenieria Genetica Biotech	Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
PE20080145A1 (es) *	2006-03-21	2008-02-11	Janssen Pharmaceutica Nv	Tetrahidro-pirimidoazepinas como moduladores de trpv1
EP2039695A4 (en)	2006-07-11	2010-09-15	Takeda Pharmaceutical	BICYCLIC HETEROCYLIC COMPOUND AND ITS USE
GB0618082D0 (en) *	2006-09-14	2006-10-25	Asterion Ltd	Growth factor
JP5489333B2 (ja)	2006-09-22	2014-05-14	メルク・シャープ・アンド・ドーム・コーポレーション	脂肪酸合成阻害剤を用いた治療の方法
AU2007301126A1 (en)	2006-09-28	2008-04-03	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
KR20090107088A (ko)	2007-02-09	2009-10-12	트랜자임 파르마 인크	거대고리 그렐린 수용체 조절제 및 이의 사용 방법
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en)	2007-06-04	2015-10-28	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2010529128A (ja) *	2007-06-08	2010-08-26	マサチューセッツインスティテュートオブテクノロジー	レット症候群および他の障害の処置
WO2009078999A1 (en)	2007-12-17	2009-06-25	Janssen Pharmaceutica N.V.	Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
US20110015181A1 (en)	2008-03-06	2011-01-20	Makoto Ando	Alkylaminopyridine derivative
EP2272841A1 (en)	2008-03-28	2011-01-12	Banyu Pharmaceutical Co., Ltd.	Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2810951B1 (en)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009261248A1 (en)	2008-06-19	2009-12-23	Banyu Pharmaceutical Co., Ltd.	Spirodiamine-diarylketoxime derivative
EP3241839B1 (en)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (ja)	2008-07-30	2010-02-04	萬有製薬株式会社	５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
WO2010047982A1 (en)	2008-10-22	2010-04-29	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5635991B2 (ja)	2008-10-30	2014-12-03	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	イソニコチンアミドオレキシン受容体アンタゴニスト
JP5557845B2 (ja)	2008-10-31	2014-07-23	メルク・シャープ・アンド・ドーム・コーポレーション	糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US8895596B2 (en)	2010-02-25	2014-11-25	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012037519A2 (en) *	2010-09-16	2012-03-22	University Of Miami	Acceleration of wound healing by growth hormone releasing hormone and its agonists
BR112013021236B1 (pt)	2011-02-25	2021-05-25	Merck Sharp & Dohme Corp	composto derivado de benzimidazol, e, composição
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9527875B2 (en)	2012-08-02	2016-12-27	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
RU2015140066A (ru)	2013-02-22	2017-03-30	Мерк Шарп И Доум Корп.	Противодиабетические бициклические соединения
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
CA2905435A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
SI3004138T1 (sl)	2013-06-05	2024-07-31	Bausch Health Ireland Limited	Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
KR102431436B1 (ko)	2014-08-29	2022-08-10	테스 파마 에스.알.엘.	α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
US10774043B2 (en)	2016-05-06	2020-09-15	Council Of Scientific & Industrial Research	Glycolactam compounds, process for preparation and uses thereof
AR109950A1 (es)	2016-10-14	2019-02-06	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (en)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
AR117122A1 (es)	2018-11-20	2021-07-14	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US11098029B2 (en)	2019-02-13	2021-08-24	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (en)	2019-02-13	2020-08-20	Merck Sharp & Dohme Corp.	Pyrrolidine orexin receptor agonists
US12312332B2 (en)	2019-08-08	2025-05-27	Merck Sharp & Dohme Llc	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
BR112023002957A2 (pt)	2020-08-18	2023-04-04	Merck Sharp & Dohme Llc	Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero
WO2025193784A1 (en) *	2024-03-12	2025-09-18	Lumos Pharma, Inc.	Pharmaceutical formulations for maintaining lean muscle mass during weight loss treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4411890A (en)	1981-04-14	1983-10-25	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
EP0669830A4 (en)	1992-11-06	1997-02-26	Merck & Co Inc	SUBSTITUTED DIPEPTIDE ANALOGS, WHICH SUPPORT THE RELEASE OF GROWTH HORMONE.
NZ258412A (en)	1992-12-11	1997-01-29	Merck & Co Inc	Spiro-fused piperidine derivatives and pharmaceutical compositions
ATE288444T1 (de)	1995-05-29	2005-02-15	Pfizer	Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
EP0766966A3 (en)	1995-09-08	2001-02-28	Eli Lilly And Company	Method of treating insulin resistance
TW432073B (en)	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
WO1998003473A1 (en)	1996-07-22	1998-01-29	Novo Nordisk A/S	Compounds with growth hormone releasing properties
WO1998010653A1 (en)	1996-09-13	1998-03-19	Merck & Co., Inc.	Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
WO1998025897A1 (en)	1996-12-12	1998-06-18	Merck & Co., Inc.	Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US6251902B1 (en) *	1997-06-25	2001-06-26	Pfizer Inc.	Dipeptide derivatives as growth hormone secretagogues
US6358951B1 (en)	1998-08-21	2002-03-19	Pfizer Inc.	Growth hormone secretagogues

1999
- 1999-08-18 US US09/377,326 patent/US6358951B1/en not_active Expired - Fee Related
- 1999-08-19 CA CA002280587A patent/CA2280587C/en not_active Expired - Fee Related
- 1999-08-19 CA CA002420425A patent/CA2420425A1/en not_active Abandoned
- 1999-08-19 ES ES99306576T patent/ES2217694T3/es not_active Expired - Lifetime
- 1999-08-19 PT PT99306576T patent/PT995748E/pt unknown
- 1999-08-19 DK DK99306576T patent/DK0995748T3/da active
- 1999-08-19 EP EP99306576A patent/EP0995748B1/en not_active Expired - Lifetime
- 1999-08-19 DE DE69915968T patent/DE69915968T2/de not_active Expired - Fee Related
- 1999-08-19 AT AT99306576T patent/ATE263168T1/de not_active IP Right Cessation
- 1999-08-20 JP JP23470499A patent/JP3486137B2/ja not_active Expired - Fee Related
- 1999-08-20 BR BR9903870-6A patent/BR9903870A/pt not_active Application Discontinuation
2001
- 2001-11-21 US US09/989,040 patent/US6559150B2/en not_active Expired - Fee Related
2002
- 2002-12-06 US US10/313,495 patent/US6686359B2/en not_active Expired - Fee Related
2003
- 2003-08-04 MX MXPA03006951A patent/MXPA03006951A/es unknown

Also Published As

Publication number	Publication date
BR9903870A (pt)	2000-10-03
CA2280587A1 (en)	2000-02-21
EP0995748A1 (en)	2000-04-26
US6559150B2 (en)	2003-05-06
JP3486137B2 (ja)	2004-01-13
US6358951B1 (en)	2002-03-19
CA2420425A1 (en)	2000-02-21
EP0995748B1 (en)	2004-03-31
CA2280587C (en)	2004-09-21
DE69915968T2 (de)	2005-03-10
PT995748E (pt)	2004-07-30
US20020045622A1 (en)	2002-04-18
US6686359B2 (en)	2004-02-03
MXPA03006951A (es)	2003-12-08
DE69915968D1 (de)	2004-05-06
ES2217694T3 (es)	2004-11-01
ATE263168T1 (de)	2004-04-15
US20030130284A1 (en)	2003-07-10
JP2000072771A (ja)	2000-03-07

Publication	Publication Date	Title
DK0995748T3 (da)	2004-08-02	Væksthormonsecerneringsfremkaldende stoffer
MY135727A (en)	2008-06-30	Heterocyclic compounds.
AP9801270A0 (en)	1999-12-18	Dipeptide derivatives.
DK1002802T3 (da)	2005-03-14	Dipeptidderivater som væksthormonsecerneringsfremkaldende stoffer
AP1043A (en)	2002-02-04	Tartrate salt of a substituted dipeptide.
JP4932132B2 (ja)	2012-05-16	成長ホルモン分泌促進薬
US20020077281A1 (en)	2002-06-20	Fracture healing using pthrp analogs
US20080045504A1 (en)	2008-02-21	Benzonitrile Derivatives to Treat Musculoskeletal Frailty
RO88703A (ro)	1986-04-30	Procedeu pentru prepararea unor peptide
WO1995003289A1 (en)	1995-02-02	Benzo-fused lactams promote release of growth hormone
JP2011514376A (ja)	2011-05-06	新規の１，２，４−トリアゾール誘導体およびそれらの製造方法
WO2004067021A1 (en)	2004-08-12	Conformationally constrained parathyroid hormone (pth) analogs with lactam bridges
WO2004093902A1 (en)	2004-11-04	CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS
US7038010B2 (en)	2006-05-02	Agents and methods for promoting bone growth
US7034050B2 (en)	2006-04-25	Pseudopeptides growth hormone secretagogues
HUP0202167A2 (en)	2002-10-28	Calcilytic compounds
US6573291B2 (en)	2003-06-03	Method and use
CN100343276C (zh)	2007-10-17	骨形成刺激剂、其合成方法及用途
WO2002056873A2 (en)	2002-07-25	2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues
WO2005105828A1 (en)	2005-11-10	Pseudopeptides growth hormone secretagogues
MXPA99012100A (en)	2000-09-04	Tartrate salt of a substituted dipeptide as growth hormone secretagogue